Stock listing

Denali Therapeutics Inc.

Selected listing: D2NL34 · BMFBOVESPA · BRL · BR

Denali Therapeutics Inc. (B3:D2NL34), Health Technology. Latest release Aug 6, 2026: Denali Therapeutics Reports Second Quarter 2026 Financial Results…

D2NL34:BMFBOVESPABRLBRUpdated October 2, 2026

Ticker: B3:D2NL34
Asset type: Stock
Sector: Health Technology
Industry: Biotechnology
Exchange: B3
Currency: BRL

About Denali Therapeutics Inc.

Denali Therapeutics Inc. is a public biotechnology company based in the United States, focused on developing therapies for neurodegenerative diseases. Denali aims to advance its innovative drug candidates to improve the lives of patients affected by these challenging conditions.

Latest news from Denali Therapeutics Inc.

Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

August 6, 2026

Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026

July 27, 2026

Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier

July 9, 2026

Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million

June 18, 2026

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease

May 20, 2026

All Denali Therapeutics Inc. news →

Research Denali Therapeutics Inc.

Denali Therapeutics Inc. company profile

View the public company page for Denali Therapeutics Inc. on 6ix.

Denali Therapeutics Inc. news

Read company news and market updates connected to Denali Therapeutics Inc..

Denali Therapeutics Inc. investor events

Find investor webinars, events, and replay context for Denali Therapeutics Inc..